Defining Fluoroquinolone Resistance-Mediating Mutations from Non-Resistance Polymorphisms in <i>Mycoplasma hominis</i> Topoisomerases

Often dismissed as a commensal, <i>Mycoplasma hominis</i> is an increasingly prominent target of research due to its role in septic arthritis and organ transplant failure in immunosuppressed patients, particularly lung transplantation. As a mollicute, its highly reductive genome and stru...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Martin Sharratt, Kirsty Sands, Edward A. R. Portal, Ian Boostrom, Brian A. Mondeja, Nadia M. Rodríguez, Lucy C. Jones, Owen B. Spiller
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/2edb7604716b44d0a02ed95ba16e6f08
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Often dismissed as a commensal, <i>Mycoplasma hominis</i> is an increasingly prominent target of research due to its role in septic arthritis and organ transplant failure in immunosuppressed patients, particularly lung transplantation. As a mollicute, its highly reductive genome and structure render it refractile to most forms of treatment and growing levels of resistance to the few sources of treatment left, such as fluoroquinolones. We examined antimicrobial susceptibility (AST) to fluoroquinolones on 72 isolates and observed resistance in three (4.1%), with corresponding mutations in the quinolone resistance-determining region (QRDR) of S83L or E87G in <i>gyrA</i> and S81I or E85V in <i>parC</i>. However, there were high levels of polymorphism identified between all isolates outside of the QRDR, indicating caution for a genomics-led approach for resistance screening, particularly as we observed a further two quinolone-susceptible isolates solely containing <i>gyrA</i> mutation S83L. However, both isolates spontaneously developed a second spontaneous E85K <i>parC</i> mutation and resistance following prolonged incubation in 4 mg/L levofloxacin for an extra 24–48 h. Continued AST surveillance and investigation is required to understand how <i>gyrA</i> QRDR mutations predispose <i>M. hominis</i> to rapid spontaneous mutation and fluoroquinolone resistance, absent from other susceptible isolates. The unusually high prevalence of polymorphisms in <i>M. hominis</i> also warrants increased genomics’ surveillance.